Retrovirus insertion site analysis of LGL leukemia patient genomes.
Genomic insertion
HERV-K
Large granular lymphocyte leukemia
Retrovirus
Visualization tool
Journal
BMC medical genomics
ISSN: 1755-8794
Titre abrégé: BMC Med Genomics
Pays: England
ID NLM: 101319628
Informations de publication
Date de publication:
17 06 2019
17 06 2019
Historique:
received:
31
01
2019
accepted:
06
06
2019
entrez:
19
6
2019
pubmed:
19
6
2019
medline:
7
1
2020
Statut:
epublish
Résumé
Large granular lymphocyte (LGL) leukemia is an uncommon cancer characterized by sustained clonal proliferation of LGL cells. Antibodies reactive to retroviruses have been documented in the serum of patients with LGL leukemia. Culture or molecular approaches have to date not been successful in identifying a retrovirus. Because a retrovirus must integrate into the genome of an infected cell, we focused our efforts on detecting a novel retrovirus integration site in the clonally expanded LGL cells. We present a new computational tool that uses long-insert mate pair sequence data to search the genome of LGL leukemia cells for retrovirus integration sites. We also utilize recently published methods to interrogate the status of polymorphic human endogenous retrovirus type K (HERV-K) provirus in patient genomes. Our data show that there are no new retrovirus insertions in LGL genomes of LGL leukemia patients. However, our insertion call tool did detect four HERV-K provirus integration sites that are polymorphic in the human population but absent from the human reference genome, hg19. To determine if the prevalence of these or other polymorphic proviral HERV-Ks differed between LGL leukemia patients and the general population, we used a recently developed tool that reports sites in the human genome occupied by a known proviral HERV-K. We report that there are significant differences in the number of polymorphic HERV-Ks in the genomes of LGL leukemia patients of European origin compared to individuals with European ancestry in the 1000 genomes (KGP) data. Our study confirms that the clonal expansion of LGL cells in LGL leukemia is not driven by the integration of a new infectious or endogenous retrovirus, although we do not rule out that these cells are responding to retroviral antigens produced in other cell types. However, our computational analyses revealed that the genomes of LGL leukemia patients carry a higher burden of polymorphic HERV-K proviruses compare to individuals from KGP of European ancestry. Our research emphasizes the merits of comprehensive genomic assessment of HERV-K in cancer samples and suggests that further analyses to determine contributions of HERV-K to LGL leukemia are warranted.
Sections du résumé
BACKGROUND
Large granular lymphocyte (LGL) leukemia is an uncommon cancer characterized by sustained clonal proliferation of LGL cells. Antibodies reactive to retroviruses have been documented in the serum of patients with LGL leukemia. Culture or molecular approaches have to date not been successful in identifying a retrovirus.
METHODS
Because a retrovirus must integrate into the genome of an infected cell, we focused our efforts on detecting a novel retrovirus integration site in the clonally expanded LGL cells. We present a new computational tool that uses long-insert mate pair sequence data to search the genome of LGL leukemia cells for retrovirus integration sites. We also utilize recently published methods to interrogate the status of polymorphic human endogenous retrovirus type K (HERV-K) provirus in patient genomes.
RESULTS
Our data show that there are no new retrovirus insertions in LGL genomes of LGL leukemia patients. However, our insertion call tool did detect four HERV-K provirus integration sites that are polymorphic in the human population but absent from the human reference genome, hg19. To determine if the prevalence of these or other polymorphic proviral HERV-Ks differed between LGL leukemia patients and the general population, we used a recently developed tool that reports sites in the human genome occupied by a known proviral HERV-K. We report that there are significant differences in the number of polymorphic HERV-Ks in the genomes of LGL leukemia patients of European origin compared to individuals with European ancestry in the 1000 genomes (KGP) data.
CONCLUSIONS
Our study confirms that the clonal expansion of LGL cells in LGL leukemia is not driven by the integration of a new infectious or endogenous retrovirus, although we do not rule out that these cells are responding to retroviral antigens produced in other cell types. However, our computational analyses revealed that the genomes of LGL leukemia patients carry a higher burden of polymorphic HERV-K proviruses compare to individuals from KGP of European ancestry. Our research emphasizes the merits of comprehensive genomic assessment of HERV-K in cancer samples and suggests that further analyses to determine contributions of HERV-K to LGL leukemia are warranted.
Identifiants
pubmed: 31208405
doi: 10.1186/s12920-019-0549-9
pii: 10.1186/s12920-019-0549-9
pmc: PMC6580525
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
88Subventions
Organisme : NCI NIH HHS
ID : R01 CA170334
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA178393
Pays : United States
Organisme : National Cancer Institute
ID : R01 CA178393
Pays : United States
Organisme : National Cancer Institute
ID : R01 CA170334
Pays : United States
Références
Viruses. 2018 Apr 06;10(4):
pubmed: 29642384
Blood. 2008 Dec 1;112(12):4609-16
pubmed: 18768393
J Virol. 1993 Jul;67(7):3763-70
pubmed: 8510205
Lancet. 1987 Mar 14;1(8533):596-9
pubmed: 2881134
PLoS Comput Biol. 2019 Mar 28;15(3):e1006564
pubmed: 30921327
Hematol Oncol. 2010 Sep;28(3):105-17
pubmed: 19645074
Front Microbiol. 2018 Mar 14;9:462
pubmed: 29593697
Genome Res. 2009 Sep;19(9):1516-26
pubmed: 19439515
Front Microbiol. 2018 Feb 20;9:265
pubmed: 29515547
Immunol Res. 2016 Feb;64(1):55-63
pubmed: 26091722
Sci Rep. 2016 Jun 27;6:28710
pubmed: 27346230
Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):E2326-34
pubmed: 27001843
BMC Biol. 2014 Sep 23;12:74
pubmed: 25246103
Genetics. 2005 Nov;171(3):1183-94
pubmed: 16157677
Cell. 1984 May;37(1):141-50
pubmed: 6327049
Annu Rev Genet. 2008;42:709-32
pubmed: 18694346
Science. 1988 Feb 19;239(4842):906-10
pubmed: 2893454
Blood. 2005 Dec 1;106(12):3926-31
pubmed: 16091452
J Exp Clin Cancer Res. 2017 Jan 26;36(1):20
pubmed: 28125999
PLoS Pathog. 2011 Feb 10;7(2):e1001274
pubmed: 21347344
Nat Rev Genet. 2016 Apr;17(4):224-38
pubmed: 26924765
Viruses. 2016 Oct 11;8(10):
pubmed: 27727192
Rev Med Virol. 2008 Nov-Dec;18(6):387-405
pubmed: 18729235
AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1647-51
pubmed: 11080805
Blood. 2011 Mar 10;117(10):2764-74
pubmed: 21190991
J Infect Dev Ctries. 2011 Nov 15;5(11):751-8
pubmed: 22112727
Leukemia. 2004 Apr;18(4):763-70
pubmed: 14961041
J Mol Evol. 2004 Nov;59(5):642-56
pubmed: 15693620
Int J Cancer. 2015 Sep 15;137(6):1249-57
pubmed: 24890612
J Virol. 1985 Mar;53(3):719-26
pubmed: 2983084
Genome Announc. 2013 Jan;1(1):
pubmed: 23405366
J Virol. 2017 Oct 13;91(21):
pubmed: 28794032
Recent Results Cancer Res. 2015;200:165-93
pubmed: 26376877
Blood. 1993 Jul 1;82(1):1-14
pubmed: 8324214
Genes Dev. 1987 Jun;1(4):366-75
pubmed: 2824282
J Virol. 1986 Jun;58(3):825-34
pubmed: 3009890
Cell. 2011 Jan 7;144(1):27-40
pubmed: 21215367
Leuk Res. 2005 Apr;29(4):381-7
pubmed: 15725471
J Virol. 1987 Sep;61(9):2659-69
pubmed: 3039159
Leuk Res. 2012 May;36(5):581-7
pubmed: 22386729
Nat Genet. 2001 Dec;29(4):487-9
pubmed: 11704760
Genome Res. 2013 Sep;23(9):1505-13
pubmed: 23657884
Genome Biol. 2015 Apr 12;16:74
pubmed: 25886262
Oncogene. 2005 Sep 5;24(39):5976-85
pubmed: 16155604
Retrovirology. 2011 Nov 08;8:90
pubmed: 22067224
AIDS Res Hum Retroviruses. 2010 Jan;26(1):33-40
pubmed: 20047475
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
Virol J. 2013 Dec 23;10:360
pubmed: 24365054
Front Oncol. 2013 Sep 17;3:243
pubmed: 24062992
J Virol. 2009 Mar;83(6):2429-35
pubmed: 19116259
Front Microbiol. 2018 Feb 13;9:178
pubmed: 29487579
PLoS Genet. 2009 Jun;5(6):e1000538
pubmed: 19557196
Virology. 1973 Apr;52(2):535-52
pubmed: 4350228
Nat Rev Cancer. 2012 Sep;12(9):639-48
pubmed: 22898541
Curr Opin Hematol. 2011 Jul;18(4):254-9
pubmed: 21546829
Br J Haematol. 1998 May;101(2):318-24
pubmed: 9609528
Cancer Biol Med. 2016 Dec;13(4):483-488
pubmed: 28154780
BMC Bioinformatics. 2009 Dec 15;10:421
pubmed: 20003500
J Mol Biol. 1990 Oct 5;215(3):403-10
pubmed: 2231712
Oncogenesis. 2019 Jan 14;8(1):6
pubmed: 30643113